Pharma import tariffs postponed as U.S. aims to push manufacturers to build locally or cut prices.
The Trump administration has postponed the planned 100% tariffs on branded pharmaceutical imports set for October 1. Instead, officials will prepare tariffs targeting companies that refuse to relocate production to the U.S. or lower drug prices. Originally, firms could avoid tariffs by building U.S. facilities. The European Union will be exempted from the new rules, continuing to pay a 15% tariff. The administration remains committed to using tariffs as leverage to reduce drug costs and bolster domestic manufacturing.
Leave a comment